scholarly journals The Role of US in Depicting Axillary Metastasis in High-Risk Breast Cancer Patients

2021 ◽  
Vol 11 (12) ◽  
pp. 1379
Author(s):  
Roxana Pintican ◽  
Magdalena Maria Duma ◽  
Madalina Szep ◽  
Diana Feier ◽  
Dan Eniu ◽  
...  
Keyword(s):  
High Risk ◽  
False Negative ◽  
P Value ◽  
Nodal Disease ◽  
Genetic Changes ◽  
The Us ◽  
Risk Patients ◽  
High Risk Breast Cancer ◽  
Risk Breast Cancer

Purpose: The aim of this study is to evaluate the role of US in depicting axillary nodal disease in high-risk patients with and without pathogenic mutations. Methods: The retrospective study included consecutive high-risk breast cancer (BC) patients who underwent a multigene testing panel for hereditary cancers, pre-operative axillary US and breast/axillary surgery. The group was divided into patients with pathogenic mutations (PM group) and patients without PM. Statistical analyses were performed using GraphPad Prism by applying Chi-square and Fisher exact tests, with a reference p-value < 0.05 and a CI of 95%. Results: Out of 190 patients with BC, 96 (51%) were negative and 94 (49%) were positive for PM as follows: 28 (25.5%) BRCA1, 16 (17%) BRCA2, 15 (16%) CHECK2, 14 (14%) RAD Group, 7 (7%) PALB, 6 (6%) NBN, 3 (3%) TP53 and ATM and 2 (2%) BARD1. US was positive in 88 of the patients, 36 with PM and 52 without PM. US and surgery (>= N1 stage) were both positive in 31 (62%) of PM patients and 44 (88%) of patients without genetic changes. There were 19 (61%) false negative US examinations in the PM group and 6 (13%) in the group without genetic changes, respectively. If the US is positive, there is a 2.6 times greater risk of positive nodes in PM patients (p-value < 0.000, 95% CI = 4.2–37.9), and a 6.2 times greater risk of positive nodes in patients without genetic changes (p-value < 0.000, 95%CI = 8.4–37.4). In the PM group, US compared to surgery reached a sensitivity = 62, with PPV = 86 and NPV = 67. In the BRCA1/2 subgroup, there is 2.5 greater times risk of nodal disease if the US is positive (p-value = 0.001, 95%CI = 2.6–76). In patients without PM, US compared to surgery reached a sensitivity = 88, PPV = 84 and NPV = 86. Conclusion: US is more sensitive in depicting axillary nodal disease in high-risk patients without PM compared to PM patients. Furthermore, there are more false negative US examinations in PM patients, compared to surgery patients.

High risk breast cancer: Prospective data about the role of FDG PET/CT in pre- and post-operative settings

2015 ◽  
Vol 41 (1) ◽  
pp. S14
Author(s):  
S. Michieletto ◽  
T. Saibene ◽  
L. Evangelista ◽  
F. Barbazza ◽  
R. Grigoletto ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Fdg Pet ◽  
Prospective Data ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Postmastectomy Radiation and Survival in Older Women With Breast Cancer

2006 ◽  
Vol 24 (30) ◽  
pp. 4901-4907 ◽  
Author(s):  
Benjamin D. Smith ◽  
Bruce G. Haffty ◽  
Arti Hurria ◽  
Deron H. Galusha ◽  
Cary P. Gross
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
High Risk ◽  
Older Women ◽  
Intermediate Risk ◽  
Postmastectomy Radiation ◽  
Risk Patients ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Purpose Clinical trials indicate that postmastectomy radiation therapy (PMRT) improves survival for women age younger than 70 years with high-risk breast cancer. However, for women age 70 years or older, the benefits of PMRT are unknown. As recent evidence suggests that certain adjuvant treatments appropriate for younger women may only be marginally beneficial for older women, we sought to determine whether PMRT improves survival for older women with breast cancer. Methods Using the Surveillance, Epidemiology and End Results Medicare data spanning 1992 to 1999, we identified 11,594 women age 70 years or older treated with mastectomy for invasive breast cancer. A proportional hazards model adjusted for clinical-pathologic covariates tested whether PMRT was associated with improved overall survival for low-risk (T1/2 N0), intermediate-risk (T1/2 N1), and high-risk (T3/4 and/or N2/3) patients. Results A total of 502 (7%) of 7,416 low-risk, 242 (11%) of 2,145 intermediate-risk, and 785 (38%) of 2,053 high-risk patients received PMRT. Median follow-up was 6.2 years. For low- and intermediate-risk patients, PMRT was not associated with survival. For high-risk patients, PMRT was associated with a significant improvement in survival (hazard ratio, 0.85; 95% CI, 0.75 to 0.97; P = .02). Five-year adjusted survival was 50% for patients not treated with PMRT or chemotherapy, 56% for patients treated with PMRT only, 57% for patients treated with chemotherapy only, and 59% for patients treated with both PMRT and chemotherapy. Conclusion PMRT is associated with improved survival for older women with high-risk breast cancer. Randomized clinical trials are urgently needed to confirm this finding and define optimal treatment strategies for this patient group.

Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy

2000 ◽  
Vol 126 (12) ◽  
pp. 722-729 ◽  
Author(s):  
Marcella Mottolese ◽  
Maria Benevolo ◽  
Girolamo Del Monte ◽  
Simonetta Buglioni ◽  
Paola Papaldo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer

Identification of high-risk breast cancer patients from genetic changes of their tumors

Surgery Today ◽  
2000 ◽  
Vol 30 (6) ◽  
pp. 516-522 ◽  
Author(s):  
Masahiro Watatani ◽  
Hiroki Inui ◽  
Koichi Nagayama ◽  
Yukihito Imanishi ◽  
Keisuke Nishimura ◽  
...  
Keyword(s):  
Breast Cancer ◽  
High Risk ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Genetic Changes ◽  
High Risk Breast Cancer ◽  
High Risk Breast ◽  
Risk Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document